Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol and Ginkgo Biloba Extract for Cognitive Function in Elderly T2DM
NCT06989697Phase 3Recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cilostazol and ginkgo biloba extract in cognitive impairment (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Mini-Mental State Examination at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
cilostazolginkgo biloba extract
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT06989697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989697.